Advances in antibody-mediated immunity against Mycobacterium tuberculosis: implications for a novel vaccine strategy.
Cell-mediated immunity is considered to be the major component of the host response against Mycobacterium tuberculosis, whereas antibody-mediated immunity historically has been considered inconsequential. In recent years, studies from several groups have challenged the traditional dogma and demonstrated that monoclonal antibodies can modify various aspects of mycobacterial infections. This review describes the experimental evidence supporting a role for antibodies in defense against mycobacterial infections and outlines future challenges to the field of antibody-mediated immunity against M. tuberculosis, with particular emphasis on the implications of these findings for a novel vaccine strategy.
Glatman-Freedman
Aharona
A
Division of Infectious Diseases, Department of Pediatrics, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Golding Building, Room 702, 1300 Morris Park Ave., Bronx, NY, USA. afreedma@aecom.yu.edu
D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000942:Antigens, Bacterial / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D014376:Tuberculosis / Q000276:immunology* / Q000517:prevention & control; D032581:Tuberculosis Vaccines / Q000276:immunology* / Q000494:pharmacology
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D016207:Cytokines; D032581:Tuberculosis Vaccines